Study of AZD2811 + Durvalumab in ES-SCLC
A phase 2 trial of Durvalumab, Carboplatin, Cisplatin in small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.
Overview
Study of AZD2811 + Durvalumab in ES-SCLC is a phase 2 interventional study registered as NCT04745689 by AstraZeneca, with 31 participants enrolled, started 2021-02-23 and due to reach its primary completion in 2022-06-18. Interventions recorded: Durvalumab, AZD2811, Carboplatin, Cisplatin, Etoposide. Conditions listed: Small-Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
Shares Durvalumab, Cisplatin, AstraZeneca, Carboplatin.
- TrialA Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer
Shares Etoposide, Cisplatin, Carboplatin, Small-cell lung cancer.
- TrialDurvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.
Shares Durvalumab, AstraZeneca, Small-cell lung cancer.
- TrialA Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small
Shares Etoposide, Durvalumab, Carboplatin, Small-cell lung cancer.
- TrialA Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following C
Shares Etoposide, Cisplatin, AstraZeneca, Carboplatin.
- TrialStudy of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
Shares Durvalumab, Cisplatin, AstraZeneca, Carboplatin.
- TrialPembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
Shares Etoposide, Cisplatin, Carboplatin, Small-cell lung cancer.
- TrialStudy to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D,
Shares Durvalumab, AstraZeneca, Small-cell lung cancer.